Loading...
Loading...
The Government of India introduced the New Drugs and Clinical Trials (Amendment) Rules, 2026, to improve and streamline the regulatory framework governing the manufacturing, testing, and approval of new drugs and investigational drugs in the country.
About the Author
Anshika Jindal, a Legal Content Writer with strong expertise in legal research and a solid academic background in BA LLB and LLM (Criminal Law). I specialize in researching statutes, case laws, and legal developments and presenting them in clear, accurate, and engaging written content. With strong analytical skills and attention to detail, I create reliable, well-structured legal content while maintaining professional and ethical standards.
I specialize in conducting in-depth legal research using credible sources and presenting legal information in a structured, reader-friendly manner while maintaining precision and authenticity. My work focuses on simplifying legal language without compromising its meaning, making legal content accessible to a wider audience.
Related articles
CDSCO Drug License Approval in India: Full Process 2026
2026-04-22
CDSCO Mandates ONDLS Portal for r-DNA Drug License Applications
2026-03-16
CDSCO Releases New Guidelines for Compounding of Offences Under the Drugs and Cosmetics Act
2026-02-26
Regulation of Medical Device Pricing and Quality in India: Key Government Measures
2026-02-20
CDSCO Releases Risk Classification List for Oncology Medical Devices
2026-02-12
Government Notifies CGHS Drug Procurement Policy 2026
2026-01-24
2026-04-23 • 0 views
2023-02-27
BIS Notifies 5 New Standards Covering Surgery Tools, Cable Products, and Medical Devices
2026-04-18
.png&w=1536&q=75)
